+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 1 Actively Recruiting clinical trials

G

Actively Recruiting

Researchers are comparing the study drug sacituzumab govitecan SG Trodelvy to standard treatments in people with extensive stage small cell lung cancer ES-SCLC who have already received prior therapy. The main goal is to see which treatment helps participants live longer by measuring overall survival. This is a global, randomized, open-label Phase 3 trial conducted to evaluate the effects of SG versus standard care in this patient population. Participants in the study are randomly assigned to one of two treatment groups. Group A receives sacituzumab govitecan intravenously at 10 mgkg on Days 1 and 8 of each 21-day cycle. Group B receives one of several approved standard treatments chosen by the investigator, including topotecan, lurbinectedin where available, or amrubicin in Japan, administered according to usual schedules in 21-day cycles. Treatment continues until disease worsens, unacceptable side effects occur, death, or other reasons for stopping treatment. During the study, participants undergo regular assessments including imaging scans to measure tumor response, physical evaluations, and laboratory tests to monitor safety. Researchers track important outcomes such as progression-free survival, response rates, duration of response, and quality of life measures related to breathing and physical function for up to 4.5 years. Safety is closely monitored by recording adverse events and laboratory abnormalities throughout the treatment and follow-up periods.

Age: 18Years +All GendersPhase 3
219 locations